Luc Van Rompaey

Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia

Pieter J. Peeters, Sophie Raynaud, Jan Cools et al. · Blood · 1997 · 481 citations · Full text

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

Juerg Schwaller, Julie Frantsve‐Hawley, Jon C. Aster et al. · The EMBO Journal · 1998 · 250 citations · Full text

Hematological Malignancy, Medicine, Hematopoietic Cell Lines +9

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology · 2013 · 225 citations · Full text

Immunology, Immunologic Mechanism, Immune Dysregulation +19

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Carsten Riether, Thomas Pabst, Sabine Höpner et al. · Nature Medicine · 2020 · 199 citations

Hematological Malignancy, Cell Therapy, Malignant Blood Disorder +7

Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634

Christel Menet, Stephen R. Fletcher, Guy Van Lommen et al. · Journal of Medicinal Chemistry · 2014 · 116 citations · Full text

Drug Target, Hit Identification, Janus Kinases +26